CTNM
NASDAQ HealthcareContineum Therapeutics, Inc. - Common stock
Biotechnology
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
๐ Market Data
| Price | $14.01 |
|---|---|
| Volume | 236,380 |
| Market Cap | 523.78M |
| Beta | 0.700 |
| RSI (14-Day) | 53.8 |
| 200-Day MA | $12.75 |
| 50-Day MA | $13.56 |
| 52-Week High | $16.91 |
| 52-Week Low | $3.80 |
| Forward P/E | -7.72 |
| Price / Book | 2.09 |
๐ฏ Investment Strategy Scores
CTNM scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (48/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (13/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CTNM in your text
Paste any article, transcript, or post โ the tool will extract CTNM and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.